Cheapest Compounded Tirzepatide: July 2026 Pricing Update

Compounded tirzepatide — the dual GLP-1/GIP receptor agonist behind brand Zepbound and Mounjaro — remains the most sought-after compounded weight loss medication. Here's where pricing stands in July 2026, along with the unique regulatory factors that make tirzepatide different from semaglutide.

July 2026 Tirzepatide Pricing

Compounded tirzepatide consistently costs more than compounded semaglutide — typically 40–60% more at equivalent therapeutic doses. This reflects the higher raw ingredient cost for tirzepatide peptide and the more complex compounding requirements.

Tirzepatide vs Semaglutide: The Clinical Case

Why do patients choose compounded tirzepatide despite the higher price? The clinical data is compelling. The SURMOUNT trials demonstrated average weight loss of 15–22% of body weight with tirzepatide, compared to 12–15% with semaglutide in the STEP trials. The dual mechanism (GLP-1 plus GIP receptor activation) appears to provide additional metabolic benefits beyond what GLP-1 activation alone achieves.

For patients who've plateaued on semaglutide or experienced insufficient response, tirzepatide often represents the logical next step. The compounded version allows the same custom titration flexibility that makes compounded semaglutide attractive — particularly the ability to escalate in smaller increments than the brand pen options permit.

Brand Alternatives to Consider

The brand-to-compounded price gap for tirzepatide has narrowed but remains meaningful — especially at higher doses where compounded pricing holds relatively steady while brand pricing escalates with dose. At the 15mg dose, compounded can save $100–$200/month over brand self-pay programs.